Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines

European Journal of Cancer

Volumn 45, Issue 9, 2009, Pages 1684-1691

  Nutt, Joyce E ^a   O'Toole, Kieran ^a   Gonzalez, David ^b   Lunec, John ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cell lines; Epidermal growth factor receptor (EGFR); Mesothelioma; Tyrosine kinase inhibitors; Vascular endothelial growth factor receptor (VEGFR)

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; VANDETANIB; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; MESOTHELIOMA; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 65849296369     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.02.022     Document Type: Article

References (32)

1. Hodgson J.T., McElvenny D.M., Darnton A.J., Price M.J., and Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 92 3 (2005) 587-593
2. Hughes A., Calvert P., Azzabi A., et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 20 16 (2002) 3533-3544
3. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 14 (2003) 2636-2644
4. Destro A., Ceresoli G.L., Falleni M., et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer 51 2 (2006) 207-215
5. Edwards J.G., Swinson D.E.B., Jones J.L., Waller D.A., and O'Byrne K.J. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer 54 3 (2006) 399-407
6. Govindan R., Kratzke R.A., Herndon II J.E., et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11 6 (2005) 2300-2304
7. Skehan P., Storeng R., Scudiero D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82 13 (1990) 1107-1112
8. Nutt J.E., Lazarowicz H.P., Mellon J.K., and Lunec J. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2. Br J Cancer 90 8 (2004) 1679-1685
9. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 76 9 (1979) 4350-4354
10. El-Obeid A., Sunnuqrut N., Hussain A., Al-Hussein K., Gutierrez M.I., and Bhatia K. Immature B cell malignancies synthesize VEGF, VEGFR-1 (Flt-1) and VEGFR-2 (KDR). Leuk Res 28 2 (2004) 133-137
11. Wood J.M., Bold G., Buchdunger E., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60 8 (2000) 2178-2189
12. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62 16 (2002) 4645-4655
13. Laird A.D., Vajkoczy P., Shawver L.K., et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60 15 (2000) 4152-4160
14. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 1 (2003) 327-337
15. Wakeling A.E., Barker A.J., Davies D.H., et al. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 38 1 (1996) 67-73
16. Learn C.A., Hartzell T.L., Wikstrand C.J., et al. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 10 9 (2004) 3216-3224
17. Zucali P.A., and Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer 42 16 (2006) 2706-2714
18. Bertino P., Porta C., Barbone D., et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 62 8 (2007) 690-695
19. Syrokou A., Tzanakakis G.N., Hjerpe A., and Karamanos N.K. Proteoglycans in human malignant mesothelioma. Stimulation of their synthesis induced by epidermal, insulin and platelet-derived growth factors involves receptors with tyrosine kinase activity. Biochimie 81 7 (1999) 733-744
20. Dobra K., Nurminen M., and Hjerpe A. Growth factors regulate the expression profile of their syndecan Co-receptors and the differentiation of mesothelioma cells. Anticancer Res 23 3B (2003) 2435-2444
21. Janne P.A., Taffaro M.L., Salgia R., and Johnson B.E. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res 62 18 (2002) 5242-5247
22. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 21 (2004) 2129-2139
23. Cortese J.F., Gowda A.L., Wali A., Eliason J.F., Pass H.I., and Everson R.B. Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma. Int J Cancer 118 2 (2006) 521-522
24. Dazzi H., Hasleton P.S., Thatcher N., Wilkes S., Swindell R., and Chatterjee A.K. Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin-embedded tissue and the F4, monoclonal antibody. Br J Cancer 61 6 (1990) 924-926
25. Soini Y., Puhakka A., Kahlos K., et al. Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1. Histopathology 39 2 (2001) 179-186
26. Strizzi L., Catalano A., Vianale G., et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193 4 (2001) 468-475
27. Ohta Y., Shridhar V., Bright R.K., et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81 1 (1999) 54-61
28. Masood R., Kundra A., Zhu S.T., et al. Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 104 5 (2003) 603-610
29. Smith N.R., James N.H., Oakley I., et al. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther 6 8 (2007) 2198-2208
30. Altomare D.A., You H., Xiao G.H., et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24 (2005) 6080-6089
31. Rascoe P.A., Cao X., Daniel J.C., Miller S.D., and Smythe W.R. Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma. J Thorac Cardiovasc Surg 130 2 (2005) 393-400
32. Tabernero J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5 3 (2007) 203-220